Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.02, MarketWatch Earnings reports.
ZYNE opened at $15.50 on Friday. Zynerba Pharmaceuticals has a one year low of $2.75 and a one year high of $15.98. The firm has a market capitalization of $293.36 million, a PE ratio of -5.94 and a beta of 5.62.
A number of research analysts have issued reports on the company. ValuEngine upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $26.00 price objective